90天死亡率与30天死亡率作为TAVR和SAVR质量指标的效用比较
IMPORTANCE: Questions have recently arisen as to whether 30-day mortality is a reasonable metric for understanding institutional practice differences after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR).…
要点
- 30天死亡率排名在90天时发生改变:TAVR为21.7%,SAVR为17.3%。
- 90天死亡率较30天死亡率与1年死亡率相关性更强,更能反映预期远期结局。
- 建议采用90天死亡率作为TAVR和SAVR术后医院绩效评价指标。
核心结论
- 基于30天死亡率的医院绩效评价可能低估结局,与90天死亡率相比会实质性歪曲TAVR和SAVR术后机构表现,即使经过风险调整亦然。
- 90天死亡率可能是衡量医院绩效和捕获手术相关死亡更可靠的结局指标。
研究设计与样本
- 全国代表性、多中心队列研究,分析2012年1月1日至2015年12月31日接受TAVR和SAVR的Medicare受益人数据。
- 排除合并冠状动脉旁路移植术及其他心脏瓣膜或重大开胸手术,并排除年手术量少于50例TAVR或70例SAVR的医院。
主要发现
- TAVR:40家医院(21.7%)在90天时绩效排名改变,其中前10%组13家(48.1%)、后10%组8家(29.6%);1年时56家(30.4%)改变,前10%组21家(77.8%)、后10%组12家(44.4%)。
- SAVR:90天总体排名转换率为17.3%,1年率为30.3%。
- 调整三组患者风险特征差异后,上述结果持续存在。
- 捕获90天事件对TAVR和SAVR术后预期1年结局的信息更稳健,主要由于观察到该时间点后瞬时风险出现平台期。
临床怎么用
- 在评价TAVR和SAVR术后医院绩效时,应考虑采用90天死亡率而非仅30天死亡率,以减少排名误判。
局限性
- 研究基于Medicare受益人数据,结论外推至其他人群需谨慎。
- 排除年手术量低的医院,可能限制结果对低容量中心的适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Questions have recently arisen as to whether 30-day mortality is a reasonable metric for understanding institutional practice differences after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR). OBJECTIVE: To examine the utility of 30-day vs 90-day mortality after TAVR and SAVR as a mortality quality metric. DESIGN, SETTING, AND PARTICIPANTS: This nationally representative, multicenter, cohort study analyzed data from Medicare beneficiaries undergoing TAVR and SAVR procedures from January 1, 2012, to December 31, 2015. Concomitant coronary artery bypass grafting and other heart valve or other major open-heart procedures were excluded. Hospitals that performed fewer than 50 TAVR or 70 SAVR procedures per year were excluded to ensure reliable estimates and to reduce the risks of inflated results because of small institutional sample sizes. Data were analyzed from October 2018 to August 2019. EXPOSURES: Hospitals were ranked into top- (10%), middle- (80%), and bottom-performing (10%) groups based on their 4-year mean 30-day mortality. MAIN OUTCOMES AND MEASURES: Changes in hospital performance rankings at 90 days and 1 year and correlation of 30- and 90-day mortality with 1-year mortality were examined. RESULTS: A total of 30 329 TAVR admissions at 184 hospitals and 26 021 SAVR admissions at 191 hospitals were evaluated. For TAVR, 40 hospitals (21.7%) changed performance rankings at 90 days: 13 (48.1%) in the top-performing group and 8 (29.6%) in the bottom-performing group. At 1 year, 56 hospitals (30.4%), which included 21 (77.8%) in the top-performing group and 12 (44.4%) in the bottom-performing group, changed rankings. Similar findings were observed for SAVR, with an overall 90-day conversion rate of 17.3% and a 1-year rate of 30.3%. These findings persisted after adjusting for the differences in patient risk profiles among the 3 groups. Capturing 90-day events was also more robustly informative regarding expected 1-year outcomes after both TAVR and SAVR, largely owing to the observed plateau in the instantaneous hazard observed beyond this point. CONCLUSIONS AND RELEVANCE: The findings suggest that evaluation of hospital performance based on 30-day mortality may underestimate outcomes and therefore substantially misrepresent institutional performance after TAVR and SAVR compared with 90-day mortality, even after risk adjustment. Although 30-day mortality has been validated, 90-day mortality may be a more reliable outcome metric for measuring hospital performance and capturing procedure-related mortality.
引用
- Hirji S, McGurk S, Kiehm S, et al. Utility of 90-Day Mortality vs 30-Day Mortality as a Quality Metric for Transcatheter and Surgical Aortic Valve Replacement Outcomes. JAMA Cardiol. 2020. PMID: 31851293. doi:10.1001/jamacardio.2019.4657
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。